Antigen-Binding Antibody Fragments Computational Identification of

Gerardo Byk and Yanay OfranAnat Burkovitz, Olga Leiderman, Inbal Sela-Culang,http://www.jimmunol.org/content/190/5/2327doi: 10.4049/jimmunol.1200757January 2013;J Immunol€2013; 190:2327-2334; Prepublished online 28MaterialSupplementary7.DC1.htmlhttp://www.jimmunol.org/content/suppl/2013/01/28/jimmunol.120075Referenceshttp://www.jimmunol.org/content/190/5/2327.full#ref-list-1This article cites 58 articles, 19 of which you can access for free at: Subscriptionshttp://jimmunol.org/subscriptionsInformation about subscribing to The Journal of Immunology is online at: Permissionshttp://www.aai.org/ji/copyright.htmlSubmit copyright permission requests at: Email Alertshttp://jimmunol.org/cgi/alerts/etocReceive free email-alerts when new articles cite this article. Sign up at:

[1]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[2]  T. Knöchel,et al.  Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. , 2008, Cancer cell.

[3]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[4]  R. Porter.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. , 1959, The Biochemical journal.

[5]  F. Karush,et al.  THE SUBUNITS OF PURIFIED RABBIT ANTIBODY. , 1964, Biochemistry.

[6]  M. Juliano,et al.  Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities , 2008, PloS one.

[7]  Yanay Ofran.  Prediction of Protein Interaction Sites , 2009 .

[8]  S. Batra,et al.  Engineering antibodies for clinical applications. , 2007, Trends in biotechnology.

[9]  V. Garsky,et al.  Peptide sequences from the hypervariable regions of two monoclonal anti-idiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. , 1992, The Journal of biological chemistry.

[10]  F. Dammacco,et al.  Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. , 2004, Immunology letters.

[11]  Janice M Reichert,et al.  Development trends for therapeutic antibody fragments , 2009, Nature Biotechnology.

[12]  P. Hudson,et al.  Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.

[13]  Donald M. O'Rourke,et al.  Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo , 2000, Nature Biotechnology.

[14]  Holger Gohlke,et al.  DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein–protein interactions , 2010, Nucleic Acids Res..

[15]  K. Tsumoto,et al.  Structural Consequences of Mutations in Interfacial Tyr Residues of a Protein Antigen-Antibody Complex , 2007, Journal of Biological Chemistry.

[16]  K. Tsumoto,et al.  Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity‐determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target , 2002, FEBS letters.

[17]  V. Ose,et al.  Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. , 1996, Human antibodies and hybridomas.

[18]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[19]  Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression. , 1985, Journal of immunology.

[20]  M Kahn,et al.  Design and synthesis of a mimetic from an antibody complementarity-determining region. , 1991, Science.

[21]  M. Berry,et al.  Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. , 1992, Journal of chromatography.

[22]  J. Scardina,et al.  Peptides Derived from the Complementarity-determining Regions of Anti-Mac-1 Antibodies Block Intercellular Adhesion Molecule-1 Interaction with Mac-1* , 1998, The Journal of Biological Chemistry.

[23]  D. Ponde,et al.  Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. , 2011, Bioorganic & medicinal chemistry letters.

[24]  Haruki Nakamura,et al.  Structural classification of CDR‐H3 revisited: A lesson in antibody modeling , 2008, Proteins.

[25]  Jinyan Li,et al.  Antibody-Specified B-Cell Epitope Prediction in Line with the Principle of Context-Awareness , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[26]  K. Tsumoto,et al.  Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. , 1994, Biochemical and biophysical research communications.

[27]  D. Pressman,et al.  Specific Binding Activity of Isolated Light Chains of Antibodies , 1967, Science.

[28]  Development of biologically active peptides based on antibody structure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Shapiro,et al.  Cardiolipin binding a light chain from lupus-prone mice. , 1998, Biochemistry.

[30]  K. Tsumoto,et al.  Crystal Structure of Anti-Hen Egg White Lysozyme Antibody (HyHEL-10) Fv-Antigen Complex , 1999, The Journal of Biological Chemistry.

[31]  G. Fields,et al.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.

[32]  Yan Li,et al.  Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. , 2005, Immunology letters.

[33]  Lora Hamuro,et al.  A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] , 2011, Journal of Lipid Research.

[34]  D. Laune,et al.  Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated from the Variable Regions of Immunoglobulins* , 1997, The Journal of Biological Chemistry.

[35]  B. Cai,et al.  Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting , 2007, Nature Biotechnology.

[36]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[37]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[38]  J. Desmet,et al.  A Combinatorial Approach for the Design of Complementarity-determining Region-derived Peptidomimetics with in Vitro Anti-tumoral Activity* , 2009, The Journal of Biological Chemistry.

[39]  G. Johnson,et al.  Preferred CDRH3 lengths for antibodies with defined specificities. , 1998, International immunology.

[40]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[41]  E. Lasonder,et al.  Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. , 1994, Journal of chromatography. A.

[42]  Andrew C. Chan,et al.  Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.

[43]  Molecular aspects of antibody-antigen interactions: size reduction of a herpes simplex virus neutralizing antibody and its antigen , 1996 .

[44]  D G Myszka,et al.  Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. , 1997, Methods in enzymology.

[45]  D. Phillips,et al.  Structure‐based design of peptides that recognize the CD4 binding domain of HIV‐1 gp120 , 1998, AIDS.

[46]  C. Selve,et al.  Reactifs de couplage peptidique I (1) - l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.) , 1975 .

[47]  P. T. Jones,et al.  Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli , 1989, Nature.

[48]  B. Persson,et al.  Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins , 1991 .

[49]  P. Pothier,et al.  Prophylactic Administration of a Complementarity-Determining Region Derived from a Neutralizing Monoclonal Antibody Is Effective against Respiratory Syncytial Virus Infection in BALB/c Mice , 1998, Journal of Virology.

[50]  J. C. Almagro,et al.  Identification of differences in the specificity‐determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires , 2004, Journal of molecular recognition : JMR.

[51]  D. Weiner,et al.  Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. , 1991, The Journal of biological chemistry.

[52]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[53]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[54]  B. Wahrén,et al.  A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Berezov,et al.  Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. , 2001, Journal of medicinal chemistry.

[56]  Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. , 2000, Biochemistry. Biokhimiia.

[57]  J. Blalock,et al.  Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. , 1988, Science.